Net profit of Bafna Pharmaceuticals reported to Rs 0.95 crore in the quarter ended December 2024 as against net loss of Rs 2.94 crore during the previous quarter ended December 2023. Sales rose 16.70% to Rs 33.19 crore in the quarter ended December 2024 as against Rs 28.44 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales33.1928.44 17 OPM %9.25-7.28 - PBDT2.62-1.67 LP PBT0.96-2.94 LP NP0.95-2.94 LP Powered by Capital Market - Live News

Bafna Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 6 February 2025.Powered by Capital Market - Live News

Net profit of Bafna Pharmaceuticals rose 5.65% to Rs 2.62 crore in the quarter ended September 2024 as against Rs 2.48 crore during the previous quarter ended September 2023. Sales declined 0.88% to Rs 40.32 crore in the quarter ended September 2024 as against Rs 40.68 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales40.3240.68 -1 OPM %9.429.83 - PBDT4.203.72 13 PBT2.622.48 6 NP2.622.48 6 Powered by Capital Market - Live News

Bafna Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 11 November 2024Powered by Capital Market - Live News

Bafna Pharmaceuticals announced that the Annual General Meeting (AGM) of the company will be held on 25 September 2024.Powered by Capital Market - Live News